Search Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsSupportive Therapy, ToxicityProtocol groupComplicationsPlasma cell neoplasmsDiseaseMultiple MyelomaOsteolysisSubgroupICD10C90.-C90.0-M89.5-MeSHMultiple MyelomaOsteolysisPlasmacytomaSequenceChemotherapyChemo-substanceChemo-substanceChemo-substanceChemo-substanceNo. Substances RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionDenosumabZoledronic AcidSupportive substanceBalanced Crystalloid SolutionDenosumabZoledronic AcidSupportive substanceBalanced Crystalloid SolutionDenosumabZoledronic AcidSupportive substanceBalanced Crystalloid SolutionDenosumabZoledronic AcidNo. Substances12Protocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationFirst lineTherapy phaseTherapy intentionsupportiveRisksBone PainDiarrheaDyspneaHeadacheHypocalcemiaHypophosphatemiaOsteonecrosis of the JawPainRenal Failure only studiesPublicationAuthorMorgan GJRaje NDiseaseNeudiagnostiziertes, multiples Myelom, Erstlinie in Kombination mit der Induktion und als Erhaltung für alle Patientenneu diagnostiziertes multiples Myelom mit mind. einer lytischen KnochenläsionOriginCenter for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, USAMRC Myelom IX StudieProtocols in Revision 2 protocols foundProtocols under revision.Denosumab 120, multiple myleoma (PID1163 V1.0)Zoledronate 4, Multiple Myeloma (PID351 V2.0)
